Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has filed an abbreviated new drug application with the FDA seeking approval to market its fentanyl buccal tablets C-II product prior to the expiration of patents owned by Cephalon.
Subscribe to our email newsletter
Watson’s fentanyl buccal tablets C-II product is a generic version of Cephalon’s Fentora C-II (fentanyl buccal tablet) which is indicated only for the treatment of breakthrough pain in opioid tolerant patients with cancer.
In its notice letter to Cephalon, Watson contends that US patents of the product are invalid, unenforceable and/or will not be infringed by Watson’s manufacture, use or sale of the product described in its abbreviated new drug application (ANDA). Based on available information, Watson believes it may be the first applicant to file an ANDA for Fentora containing a paragraph IV certification under the provisions of the Hatch-Waxman Act and, should its product be approved, may be entitled to 180 days of generic market exclusivity.